Vendor Intelligence Report: Maddox Research

Executive summary

Across 4 Finnrick lab tests, Maddox Research has 3 pass / 1 fail, for an overall pass rate of 75%. The record is narrow and product-specific: Retatrutide is the only product in the supplied Finnrick dataset. That makes Maddox a conditional Retatrutide consideration rather than a tested catalog-wide vendor, especially because the same short record contains an identity-failure concern and becomes less reassuring under stricter scoring.

The public-facing business story is thinner than the marketing language. Maddox claims COA-verified, third-party-tested peptides, but investigators did not identify the testing labs, a public batch-verification portal, or disclosed scientific personnel. The order site and the education/marketing site share infrastructure, yet the captured ordering flow lacked working Terms and Privacy pages, leaving buyers with weak documentation around recourse, privacy, and the legal seller.

The accountability trail points to a Virginia LLC but not transparent ownership. Registry and web records show a residential-address signal, a commercial registered agent, privacy-protected domains, and no public founder or quality lead. A personal-name peer-to-peer payment handle links the purchase flow to a likely operator whose visible background is engineering rather than pharmaceutical manufacturing; a separate marketing/business-development signal appears, but no pharma-backed corporate sponsor was established.

For buyers, the directional read is simple: Maddox is only plausibly defensible where the tested product matches the lot being considered, and even then batch-specific proof matters. For anything outside Retatrutide, this report found no product-specific Finnrick safety basis.

Inside the full report:

• Finnrick Retatrutide test trajectory, methodology-divergence chart, and Appendix A laboratory table
• Virginia LLC filing trail, residential-address signal, and unrelated UK name-collision analysis
• Two-domain infrastructure review for mdxresearch.deals and maddoxresearch.ai
• COA, third-party-lab, Terms of Service, and Privacy Policy verification checks
• Personnel and payment-rail mapping covering peer-to-peer payment identifiers and disclosed role signals
• Affiliate/reputation sweep across X, coupon, web, and Reddit surfaces with coverage gaps noted

Risk assessment

• Retatrutide identity-failure risk — high: Finnrick’s Retatrutide record contains 4 tests with 3 pass / 1 fail, and the field Finnrick capture identified the failure as an identity-failure concern.
• Retatrutide batch-consistency risk — medium: The same tested product has a mixed pass/fail record and methodology-sensitive ratings; buyers should verify the specific Retatrutide lot rather than relying on brand-level claims.
• Untested-catalog risk — medium: Finnrick’s supplied Maddox data covers Retatrutide only; no product-specific Finnrick record supports other Maddox peptides.
• Ownership and accountability opacity risk — high: Public records show a Virginia LLC with a residential-address signal and commercial registered agent, while public sites do not disclose owners, officers, or a quality lead.
• COA and third-party lab verification risk — high: Maddox claims COA-verified, third-party-tested peptides, but the supplied materials did not identify the labs or a public COA-verification mechanism, and the Retatrutide record includes a failure.
• Ordering-site legal recourse risk — medium: Terms of Service and Privacy Policy pages on the order site returned 404s at capture; a separate AI-site privacy page was incomplete.
• Personal payment and chargeback risk — medium: Payments used Cash App $JimmyLAGDA and Zelle mdxpeptides@gmail.com, offering limited buyer protection compared with conventional merchant processing.
• Scientific-credential mismatch risk — medium: Identified personnel signals point to engineering, retail, EdTech, and business-development backgrounds; no pharmaceutical, chemistry, or laboratory credentials were verified.